Down syndrome (DS) is typically caused by an extra chromosome 21 in the cell nucleus (trisomy 21, or T21). T21 is both the most common cause of genetically defined intellectual disability and the earliest documented cause of Alzheimer's disease (AD)-type pathology. Currently, all presymptomatic individuals with DS are classified as having 'Stage 0' DS-associated AD (DSAD). DSAD pathology evolves inexorably, with virtually all individuals with DS developing AD pathology by age 40, and approximately 50% meeting clinical dementia diagnosis criteria at 55 years of age. This study will test the hypothesis that the FDA-approved AD drug memantine, at higher-than-standard doses, may be effective as a cognitive enhancer in adolescents and young adults with DS. The primary goal of this phase 1b clinical trial will be the assessment of the safety and tolerability of three memantine doses in persons with DS. In addition, we will assess the effect of this drug on cognitive test scores and plasma biomarkers of AD in the study participants. Finally, we will also investigate steady-state plasma levels of memantine and the time course of memantine plasma levels after a single dose in the study participants (pharmacokinetics, or PK). The data generated through this phase 1b study will provide the essential safety, PK, and preliminary efficacy signals required to advance a phase 2 trial evaluating high-dose memantine as a first-in-class therapeutic strategy in DS.

Start Date01 Jun 2026

Sponsor / Collaborator

University Hospitals Cleveland Medical Center

NCT07248228

/ Not yet recruitingPhase 2IIT

A Randomized Phase 2 Trial of Memory Avoidance Whole Brain Radiotherapy Versus Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)

Participants in this research study have cancer that has spread to their brain, called brain metastases. One treatment for this type of cancer is called whole brain radiotherapy that stays away from a specific neurocognitive substructure, called the hippocampus, combined with medication to preserve cognitive function. This study compares that approach to another approach of whole brain radiotherapy that stays away from additional structures that are thought to have a role in cognitive function. Researchers want to see if there is a difference in the preservation of cognitive function between these two approaches.

Start Date01 May 2026

Sponsor / Collaborator

The Case Comprehensive Cancer Center

NCT07139834

/ Not yet recruitingPhase 1IIT

Examining the Effects of Escitalopram and Memantine on Pattern Separation in Major Depressive Disorder

This study seeks to examine the effects of treatment with a selective serotonin reuptake inhibitor (SSRI), escitalopram, a first-line treatment for depression, in combination with placebo or with extended-release memantine, on neuropsychological function, regional brain activity assessed by functional magnetic resonance imaging, and depressive symptoms, in participants with Major Depressive Disorder. Escitalopram is administered in an open-label fashion in this study; extended release memantine is administered in a double-blind, randomized, placebo-controlled manner.

Start Date01 Apr 2026

Sponsor / Collaborator

The New York State Psychiatric Institute

100 Clinical Results associated with Memantine hydrochloride

100 Translational Medicine associated with Memantine hydrochloride

100 Patents (Medical) associated with Memantine hydrochloride

5,398

Literatures (Medical) associated with Memantine hydrochloride

01 May 2026·BEHAVIOURAL BRAIN RESEARCH

Early administration of a low dose of memantine prevents neurological symptoms, neuronal loss and attenuates infarct size in a rat stroke model

Article

Author: Martínez-Torres, Nestor I ; Torres-Méndoza, Blanca Miriam ; Marquez-Pedroza, Jazmin ; Cárdenas-Bedoya, Jhonathan

RATIONALE:

Memantine (Mem), an uncompetitive antagonist of the N-methyl-D-aspartate receptor (NMDAr), has demonstrated neuroprotective effects in preclinical stroke models by reducing excitotoxic damage. However, the efficacy of low acute doses administered during the immediate post-ischemic phase remains insufficiently characterized.

METHODS:

Male rats underwent permanent middle cerebral artery occlusion (pMCAO) and received a single intraperitoneal dose of Mem (5 mg/kg) two hours post-occlusion. Neurological deficits were assessed using the modified Neurological Severity Score (mNSS). Infarct area and neuronal preservation were quantified using MAP2 immunohistochemistry. BDNF and PSD95 protein levels were measured by ELISA, and their gene expression was evaluated via RT-PCR.

RESULTS:

Mem treatment significantly reduced infarct area (p = 0.000029) and attenuated neurological deficits (p < 0.0001). MAP2 immunoreactivity was higher in the Mem-treated group (p = 0.000003), indicating preservation of neuronal structure. BDNF protein levels did not differ between the pMCAO and pMCAO+Mem groups; PSD95 protein and its corresponding DLG4 mRNA were increased in the pMCAO group compared with Sham. In the other groups, levels remained unchanged.

CONCLUSION:

Early administration of low-dose memantine confers acute neuroprotection after stroke by reducing tissue damage and preserving neuronal integrity, without affecting ischemia-induced BDNF and PSD95 protein and gene expression. These findings suggest a selective early neuroprotective mechanism and highlight the need for long-term and sex-inclusive studies to further evaluate memantine's therapeutic potential.

01 May 2026·BRAIN BEHAVIOR AND IMMUNITY

Targeting α7nAChR-driven brain endothelial pyroptosis mitigates HIV-1 gp120-induced blood–brain barrier breakdown

Article

Author: Chen, Jingyu ; Huang, Pengwei ; Cao, Hong ; Zhou, Bingliang ; Chen, Jie ; Zou, Jinhu ; Gao, Xuefeng ; Meng, Xiangshun

HIV-1-associated neurocognitive disorder (HAND) persists in over 40% of people with HIV despite effective antiretroviral therapy, underscoring the absence of targeted interventions. Disruption of the blood-brain barrier (BBB) is a hallmark of HAND, yet the mechanisms that link viral proteins to endothelial injury remain insufficiently understood. This study demonstrates that the HIV-1 envelope glycoprotein gp120 induces pyroptosis of brain microvascular endothelial cells (BMECs), thereby compromising BBB integrity. This process is mediated by the α7 nicotinic acetylcholine receptor (α7nAChR)-dependent activation of the ROS/NF-κB/NLRP3 inflammasome axis. Unexpectedly, α7nAChR, typically regarded as anti-inflammatory, exhibits a paradoxical pathogenic role under HIV-1 gp120 exposure, driving inflammatory endothelial cell death rather than protection. Importantly, this detrimental pathway is effectively inhibited by two clinically approved drugs, memantine and metformin, through suppression of α7nAChR. These findings uncover endothelial pyroptosis as a previously unrecognized mechanism of gp120-induced BBB disruption, redefine the functional role of α7nAChR in HAND pathogenesis, and highlight a promising therapeutic strategy through drug repurposing. By revealing a targetable pathway with direct clinical applicability, this work provides mechanistic insights and translational opportunities for preserving BBB function in HIV-associated neuropathology.

01 May 2026·JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Integrative structure-based approach for phytocompound-based dual therapeutics targeting Alzheimer's and Parkinson's disease

Article

Author: Das, Shovon Kumar ; Khanom, Taslima ; Ahammed, Tanbir ; Kumar, Pawan ; Faruk, Md Ashraf Zaman ; Islam, Md Tahsinul ; Billah, Md Motashim ; Akter, Fahmida ; Enan, Md Eshak ; Pulok, Md Mehedi Hasan ; Abdullah, Md ; Hossain, Md Siam ; Khaled Bhuiyan, Abul Fateh Md ; Islam, Md Sharyful ; Azmi, Azhar Mahmud

Neurodegenerative diseases like Alzheimer's and Parkinson's are growing global health concerns with limited treatment options. In this study, we explored four natural compounds-Baicalein, Vincarubine, Rutin, and Luteolin-for their potential as multi-target drugs using computational methods. These compounds were tested against key proteins involved in disease progression, including LRRK2, APP, and Tau kinase. Molecular docking showed that Vincarubine had the strongest binding with LRRK2 and APP, while Rutin interacted best with Tau kinase. Molecular dynamics simulations further supported Rutin's strong and stable binding, with low fluctuation and deviation values. Although Vincarubine showed high binding affinity, it also displayed greater structural flexibility, suggesting it may need some modifications for better stability. Pharmacokinetic analysis revealed that most of the compounds followed drug-likeness rules, but Rutin and Vincarubine had some limitations in size and brain permeability, meaning advanced delivery systems like nanoparticles may be needed. Toxicity tests showed that Baicalein and Rutin were generally safe, while Vincarubine had potential risks for the kidneys and lungs. When compared to commonly used drugs like Donepezil, Memantine, and Levodopa, these natural compounds showed even better binding strength and stability in simulations. Overall, the results suggest these phytocompounds could be promising candidates for treating neurodegenerative diseases. However, further lab-based studies, both in cells and animals, are essential to confirm their real-world potential. Future research should be focused on improving their structures, delivery methods, and possible combinations to boost their effectiveness.

124

News (Medical) associated with Memantine hydrochloride

29 Apr 2026

·www.biospace.com

Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

Management to host conference call on Thursday, May 14, 2026 at 4:30pm ET VANCOUVER, B.C. & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 14, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its first quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website at . Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: Participant Listening : 1-877-407-9039 or 1-201-689-8470 or Participants can use guest dial-in #s above and be answered by an operator, or click the Call me™ link for instant telephone access to the event. Call me™ link will be made active 15 minutes prior to scheduled start time. The live audio webcast will be accessible here: A replay of the earnings call is available after the conference call has ended. Replay Dial-In: 1-844-512-2921 or 1-412-317-6671 Access ID: 13760339 Replay Webcast : About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL® is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company’s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Form 10-K as filed with the SEC on March 31, 2026 and available at . These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law. Contacts For further information: Investor Relations IR@alphacognition.com

Drug ApprovalFinancial Statement

27 Apr 2026

·www.businesswire.com

Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition, Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that Michael McFadden, Chief Executive Officer, will participate in three investor conferences in May. Event details are as follows: Market Movers Investor Summit Format: Presentation and 1x1 meetings Date/Time: Tuesday, May 5 at 2:40 p.m. ET H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq Format: Fireside Chat and 1x1 meetings Date/Time: Tuesday, May 19 at 4:30 p.m. ET Craig Hallum’s 23rd Annual Institutional Investor Conference Format: 1x1 meetings Date: May 28, 2026 A live webcast of select presentations will be accessible in the Events & Presentations section of the Company’s investor relations website and archived for replay following the events. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Such statements include but are not limited to statements regarding the future success of the commercialization of ZUNVEYL, statement regarding the timing and potential outcomes of the Company’s ongoing clinical and preclinical studies, statements regarding future presentations, statements regarding potential product approvals and other statements regarding the future anticipated operations of the Company. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot ensure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to continue to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company’s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability, risks related to our ongoing clinical trials and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at www.sedar.com and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC on March 31, 2025 and the Company’s other filings with the SEC available at www.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.

Drug Approval

27 Apr 2026

·www.biospace.com

Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences - April 27, 2026

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)-- Alpha Cognition, Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that Michael McFadden, Chief Executive Officer, will participate in three investor conferences in May. Event details are as follows: Market Movers Investor Summit Format: Presentation and 1x1 meetings Date/Time: Tuesday, May 5 at 2:40 p.m. ET H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq Format: Fireside Chat and 1x1 meetings Date/Time: Tuesday, May 19 at 4:30 p.m. ET Craig Hallum’s 23 rd Annual Institutional Investor Conference Format: 1x1 meetings Date: May 28, 2026 A live webcast of select presentations will be accessible in the Events & Presentations section of the Company’s investor relations website and archived for replay following the events. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Such statements include but are not limited to statements regarding the future success of the commercialization of ZUNVEYL, statement regarding the timing and potential outcomes of the Company’s ongoing clinical and preclinical studies, statements regarding future presentations, statements regarding potential product approvals and other statements regarding the future anticipated operations of the Company. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot ensure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to continue to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company’s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability, risks related to our ongoing clinical trials and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC on March 31, 2025 and the Company’s other filings with the SEC available at These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law. Contacts For further information: Investor Relations LifeSci Advisors, PJ Kelleher pkelleher@lifesciadvisors.com

100 Deals associated with Memantine hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D04905	Memantine hydrochloride	N06DX01	DB01043

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Alzheimer Disease	European Union	H. Lundbeck A/S	15 May 2002
Alzheimer Disease	Iceland	H. Lundbeck A/S	15 May 2002
Alzheimer Disease	Liechtenstein	H. Lundbeck A/S	15 May 2002
Alzheimer Disease	Norway	H. Lundbeck A/S	15 May 2002
Dementia	Germany	H. Lundbeck A/S	11 Aug 2000

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dementia, Vascular	Phase 3	Russia	Merz Pharmaceuticals GmbH	23 Jan 2018
Frontotemporal Dementia	Phase 3	Canada	H. Lundbeck A/S	01 Oct 2007
Multiple Sclerosis, Relapsing-Remitting	Phase 3	France	H. Lundbeck A/S	01 Sep 2005
Amyotrophic Lateral Sclerosis	Phase 3	Portugal	H. Lundbeck A/S	01 Jul 2005
Agitation	Phase 3	United States	Forest Laboratories LLC	01 Sep 2004
Cognitive Dysfunction	Phase 3	United States	Forest Laboratories LLC	01 Apr 2004
Multiple Sclerosis	Phase 3	United States	Forest Laboratories LLC	01 Apr 2004
Multiple Sclerosis, Primary Progressive	Phase 3	United States	Forest Laboratories LLC	01 Apr 2004
Dementia due to Alzheimer's disease (disorder)	Phase 3	Canada	H. Lundbeck A/S	01 Dec 2003
Glaucoma, Open-Angle	Phase 3	-	Allergan UC	01 Mar 1999

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06501638 (Pubmed \| Circulation)	Phase 2	Atrial Premature Complexes	241	Memantine	itlsyhgqzd(apbeotqlay): Difference (%) = 47.1, P-Value = 0.0045 View more	Positive	19 Mar 2026
				Placebo
NCT05801380 (PHRR230220-0054116, Pubmed \| J Alzheimers Dis Rep)	Not Applicable	Alzheimer Disease	2	MemantineDonepezil + MemantineDonepezil	mjhesgoiah(sazugwajvz) = xvnbjzkfnr eskjtzvkvw (qxngcqvwqx ) View more	Negative	01 Mar 2026
NCT03703856 (CTgov)	Phase 4	Alzheimer Disease	53	Memantine	wcbnrzzzzt(dgbfdidvli) = mxoentcavu sezslmxqtq (edunkwbvmp, 8.97) View more	-	07 Jan 2026
NCT01972074 (Pubmed \| JAMA Netw Open)	Phase 2	Autism Spectrum Disorder	42	Memantine	pdfpmcwjaq(vszflfzcdq) = rkhwzybbyx gjgkrpmzzv (srgcnkmqto ) View more	Positive	01 Oct 2025
				Placebo	pdfpmcwjaq(vszflfzcdq) = vdnhnptlzk gjgkrpmzzv (srgcnkmqto ) View more
NCT01535040 (CCCWFU 99311, Pubmed \| Cancer Control)	Phase 2	Smoking Cessation	130	Memantine 10 mg	ikftzdjzxh(ispmtdnduu) = eqviiwraqe uizxbkzwfo (eejhofnvng )	Negative	01 Aug 2025
				Placebo	ikftzdjzxh(ispmtdnduu) = hjbotzsrfe uizxbkzwfo (eejhofnvng )
NCT04117178 (MONANTI, CTgov)	Phase 4	Alzheimer Disease \| Dementia due to Parkinson's disease \| Lewy Body Disease	132	Measurement of serum level of anti-dementia drug (Standard of Care)	pqfcdnqbri(jqcqmrieee) = ealgsxiull dwtkdnsdrt (xuopgmhiad, 3.19) View more	-	10 Feb 2025
				Measurement of serum level of anti-dementia drug+Memantine+Donepezil (Intervention Arm)	pqfcdnqbri(jqcqmrieee) = ifwnswjbho dwtkdnsdrt (xuopgmhiad, 3.56) View more
NCT04302870 (MND SMART, Pubmed)	-	Motor Neuron Disease	554	美金刚	dorxykaoll(cbprzydaew) = rtckjcmxbr bpvtaplvhx (zcpkslxeod )	Negative	19 Sep 2024
				曲唑酮	dorxykaoll(cbprzydaew) = lswwefuvii bpvtaplvhx (zcpkslxeod )
NCT04792645 (CTgov)	Phase 2	Trichotillomania \| Skin Diseases	100	Placebo (Placebo)	zebxalmwnp(flcagfaxvx) = xvnkrpkcqz oddtohmsmk (snqeihjkhr, 2.80) View more	-	01 Aug 2023
				Memantine (Memantine)	zebxalmwnp(flcagfaxvx) = driosnweuz oddtohmsmk (snqeihjkhr, 3.65) View more
NCT04698525 (CTgov)	Phase 3	Migraine Disorders	33	Valproate Sodium (Valproate Group)	abjiwmzcmw(wxolbbbsal) = xqkvxwmwug hqznrppjtn (hxqcowkloe, 1.11) View more	-	17 May 2023
				Memantine (Memantine)	abjiwmzcmw(wxolbbbsal) = sqlvfluqpe hqznrppjtn (hxqcowkloe, 1.5) View more
NCT03860597 (CTgov)	Phase 4	Schizoaffective disorder \| Schizophrenia	42	Placebo+Memantine (Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine)	qpemfrwwob(lpjwfhhkad) = yhqjumbadx oqybqrwxfn (rbgfppqiou, 5.11) View more	-	21 Dec 2022
				Placebo+Memantine (Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo)	qpemfrwwob(lpjwfhhkad) = xmmasjwfhl oqybqrwxfn (rbgfppqiou, 6.77) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis